VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) - - Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is pleased to announce it has closed the acquisition to acquire 100% of the issued and outstanding shares of NoBrainer Imaging Centers, Inc. (“NIC”) (the “Transaction”) previously announced on... Read More

First Clinic Targeted to Open Q4, 2025 in the U.S. VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is pleased to announce it has entered into share exchange agreements to acquire 100% of the issued and outstanding shares of NoBrainer Imaging... Read More

VANCOUVER, British Columbia, May 05, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a Canadian clinical stage pharmaceutical development company announces that it has extended the expiry date of an aggregate of 4,752,969 outstanding warrants (the “ 2023 Warrants ”). The 2023 Warrants were issued in connection with the closing of a rights... Read More

VANCOUVER, British Columbia, April 08, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has received a notice of allowance from the European Patent Office (EPO) for patent application 19827430.0 for its lead chronic kidney disease (CKD) program drug... Read More

VANCOUVER, British Columbia, March 06, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its wholly owned subsidiary Algernon NeuroScience (AGN Neuro), has appointed Netcapital Securities Inc. (“Netcapital Securities”), a FINRA-registered broker-dealer,... Read More

VANCOUVER, British Columbia, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its wholly owned subsidiary, Algernon NeuroScience (AGN Neuro), has appointed Dr. Sándor Nardai as the Principal Investigator (PI) for its upcoming randomized,... Read More

VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its wholly owned subsidiary, Algernon NeuroScience (AGN Neuro), has appointed Validcare as the contract research organization (“CRO”) for the Company’s upcoming... Read More

VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a Canadian clinical stage pharmaceutical development company announces that it has extended the expiry date of an aggregate of 4,752,969 outstanding warrants (the “ 2023 Warrants ”). The 2023 Warrants were issued in connection with the closing of a rights... Read More

VANCOUVER, British Columbia, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a Canadian clinical stage pharmaceutical development company announces the close of its non-brokered private placement, previously announced on August 7, 2024 and updated on August 13, 2024, for gross proceeds of $235,200 (the “ Offering ”) of units (the “... Read More

VANCOUVER, British Columbia, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a Canadian clinical stage pharmaceutical development company announces an increase to its non-brokered private placement, previously announced on August 7, 2024, from gross proceeds of $150,000 to $235,200 (the “ Offering ”) of units (the “ Units ”) at an... Read More

VANCOUVER, British Columbia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a Canadian clinical stage pharmaceutical development company announces a non-brokered private placement for gross proceeds of $150,000 (the “ Offering ”) of units (the “ Units ”) at an issue price of $0.12 per Unit. Each Unit will consist of one Class A... Read More

VANCOUVER, British Columbia, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a Canadian clinical stage pharmaceutical development company announces the close of its non-brokered private placement, previously announced on July 11, 2024 and updated on July 31, 2024, for gross proceeds of $408,000 (the “ Offering ”) of units (the “... Read More

VANCOUVER, British Columbia, July 31, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a Canadian clinical stage pharmaceutical development company announces an increase to its non-brokered private placement, previously announced on July 11, 2024, from gross proceeds of $250,000 to $408,000 (the “ Offering ”) of units (the “ Units ”) at an... Read More

VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to report that ifenprodil achieved a 93% (p = 0.036) reduction in median cough count in an acute guinea pig citric acid challenge study. The multi-dose study was conducted under the direction of... Read More

VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a Canadian clinical stage pharmaceutical development company announces a non-brokered private placement for gross proceeds of $250,000 (the “ Offering ”) of units (the “ Units ”) at an issue price of $0.12 per Unit. Each Unit will consist of one Class A... Read More

VANCOUVER, British Columbia, May 21, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has engaged the services of ICP Securities Inc. ("ICP") to provide automated market making services, including use of its proprietary algorithm, ICP Premium™. ICP... Read More

VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), along with the Centre for Human Drug Research (CHDR), will present its Phase 1 stroke study data at the... Read More

VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to invite investors and other interested parties to participate in an upcoming special CEO interview and Q & A session on April 16 th , 2024, at 4 PM ET / 1 PM PT, hosted by Market Radius Research. Martin Gagel of Market Radius Research and CEO... Read More

VANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it plans to move forward with its intravenous formulation of its AP-188 (“N,N-Dimethyltryptamine” or “DMT”) stroke research program as its lead asset, after having sold... Read More

VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has closed on its agreement with Seyltx Inc. (“Seyltx”), a privately owned U.S. based drug development company, for the acquisition of Algernon’s NP-120... Read More

VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has received a notice of intention to grant from the Chinese Patent Office for patent application No. 201980043698.6 for its antifibrotic drug candidate NP-251... Read More

VANCOUVER, British Columbia, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company is pleased to announce that it has received a notice of allowance from the Japanese Patent Office for patent application No. 2021-547495 entitled: Compositions and Methods for Treating Idiopathic... Read More

VANCOUVER, British Columbia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a Canadian clinical stage pharmaceutical development company announces the close of its non-brokered private placement, previously announced on December 12, 2023 and updated on December 27, 2023, for gross proceeds of $280,000 (the “ Offering ”) of units... Read More

VANCOUVER, British Columbia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a Canadian clinical stage pharmaceutical development company announces an increase to its non-brokered private placement, previously announced on December 12, 2023, from gross proceeds of $150,000 to $280,000 (the “ Offering ”) of units (the “ Units ”) at... Read More

VANCOUVER, British Columbia, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a Canadian clinical stage pharmaceutical development company announces a non-brokered private placement for gross proceeds of $150,000 (the “ Offering ”) of units (the “ Units ”) at an issue price of $0.075 per Unit. Each Unit will consist of one Class A... Read More

VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc . (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has received a notice of intention to grant from the Chinese Patent Office for patent application No. 112654357 entitled “Compositions and Methods for Treating... Read More

VANCOUVER, British Columbia, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has signed a Letter of Intent (“LOI”) with Seyltx Inc. (“Seyltx”), a privately owned U.S. based drug development company, to acquire Algernon’s NP-120 (“Ifenprodil”)... Read More

VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has received a Notice of Allowance from the Japanese Patent Office for patent application No. 2021-512244 entitled “Compositions and Methods for Treating Non-Alcoholic... Read More

VANCOUVER, British Columbia, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is pleased to announce that it has been issued a patent from the United States Patent and Trademark Office (USPTO), No. 11744808, for its lead chronic kidney Disease (CKD) program drug NP-251 (Repirinast),... Read More

VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke... Read More

VANCOUVER, British Columbia, July 14, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”), a Canadian clinical stage pharmaceutical development company, announces a non-brokered private placement for gross proceeds of CDN$205,000 (the “ Offering ”) of units (the “ Units ”) at an issue price of CDN$0.20 per Unit. Each Unit will consist of one... Read More

VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is pleased to announce that it has engaged Maxim Group LLC (“Maxim”) to provide financial advisory and investment banking services, and to assist in identifying and evaluating potential M&A and strategic... Read More

VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company is pleased to announce that it will present its Phase 2a Ifenprodil cough data at the 9 th American Cough Conference (ACC) being held June 9-10, 2023 in Reston, Virginia. The ACC is the world's... Read More

VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to advise that its subsidiary Algernon NeuroScience (AGN Neuro), has successfully completed dosing of the third and planned final cohort in its escalating dose Phase 1 clinical study of... Read More

Vancouver, British Columbia, May 31, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that it has received a Notice of Allowance from the Japanese Patent Office (JPO) for patent application 2021-522114 entitled “Compositions and Methods for Treating Chronic Kidney... Read More

VANCOUVER, British Columbia, May 05, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a Canadian clinical stage pharmaceutical development company announces that it has closed its previously announced rights offering which expired on April 27, 2023 (the “ Rights Offering ”). At closing, the Company issued 4,753,369 units (the “ Units ”) at... Read More

VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is reminding its shareholders of the details of its previously announced rights offering as well as the cut off date and time for the exercise of those rights. On March 21, 2023, Algernon announced it was... Read More

VANCOUVER, British Columbia, April 17, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is pleased to announce that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 17/258,402 entitled “Compositions and Methods for Treating... Read More

VANCOUVER, British Columbia, April 04, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to advise that its subsidiary Algernon NeuroScience (AGN Neuro), has completed dosing of the second cohort in its escalating dose Phase 1 clinical study of an intravenous formulation... Read More

VANCOUVER, British Columbia, April 03, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its wholly owned subsidiary, Algernon NeuroScience (AGN Neuro), has qualified its Form 1-A offering statement filed with the U.S. Securities and Exchange Commission... Read More

VANCOUVER, British Columbia, March 21, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces it is undertaking a rights offering to raise gross proceeds of approximately $2,416,747 (the “Rights Offering”). The Company will be offering 9,666,988 rights (the “Rights”) to holders (the... Read More

VANCOUVER, British Columbia, March 02, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro) has appointed Dr. David L. Brody as a consultant for its clinical research program for the treatment of Traumatic Brain Injury... Read More

VANCOUVER, British Columbia, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company announces that effective at the opening of markets on March 3, 2023, the Class A Common Shares (the “Common Shares”) of the Company will commence trading following a four-for-one forward share split (the... Read More

VANCOUVER, British Columbia, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro) has added a new clinical research program for the treatment of Traumatic Brain Injury (TBI) with AP-188 (“N,N-Dimethyltryptamine or... Read More

VANCOUVER, British Columbia, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to advise that its subsidiary Algernon NeuroScience (AGN Neuro), has completed dosing of the first cohort in its Phase 1 clinical study of an intravenous formulation of AP-188... Read More

VANCOUVER, British Columbia, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to advise that its subsidiary, Algernon NeuroScience (AGN Neuro), has dosed the first subject in its Phase 1 clinical study of an intravenous formulation of AP-188... Read More

VANCOUVER, British Columbia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has appointed Dr. Peter Dicpinigaitis MD, Professor of Medicine at the Albert Einstein College of Medicine, in New York, as a medical consultant to the Company’s... Read More

VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it is planning a 180 patient, 90-day Phase 2b clinical study of NP-120 (“Ifenprodil”) for chronic cough to begin in Q3 of 2023. Ifenprodil is an N-methyl-D-aspartate... Read More

VANCOUVER, British Columbia, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has established Algernon NeuroScience (AGN Neuro), a new wholly-owned private subsidiary of AGN Pharma, to advance the Company’s psychedelic DMT stroke program. The... Read More

VANCOUVER, British Columbia, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that the United States Food and Drug Administration (“U.S. FDA”) has granted Orphan Drug Designation (ODD) to Ifenprodil as a treatment for Idiopathic Pulmonary Fibrosis... Read More

VANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has commenced screening subjects for its Phase 1 clinical study of an intravenous formulation of AP-188 (“N,N-Dimethyltryptamine” or “DMT”) in the Netherlands. The... Read More

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has entered an Investigator-Initiated Clinical Trial Agreement (“CTA”) with Yale University (“Yale”) for the investigation of multiple intravenous doses of DMT for the treatment of depression. The trial’s principal investigator is Professor... Read More

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce that Dr. Rick Strassman, author of the book DMT: The Spirit Molecule and Algernon consultant, will be joining CEO Christopher J. Moreau for the Science Keynote Address at Wonderland, the world-leading event in the psychedelic medicine... Read More

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has recently received a cash payment of approximately CDN $450K from a refundable tax credit program from its clinical research work in Australia. “Algernon tries to conduct as much of its clinical research in Australia as possible... Read More

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has decided to advance its investigation of NP-120 (Ifenprodil) for IPF with cough as its key indication. As a result, the Company further announces it has filed a request for Orphan Designation with the United States Food and Drug... Read More

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has received approval to conduct a Phase 1 clinical study of an intravenous formulation ("IVF") of AP-188 (“N,N-dimethyl tryptamine” or “DMT”) for the treatment of stroke in the Netherlands from the Stichting Beoordeling Ethiek Biomedisch... Read More

Microdose Psychedelic Insights , the leading guide to the business of psychedelics, is thrilled to announce Algernon Pharmaceuticals (CSE: AGN) (FSE: AGW0) (OTCQB: AGNPF) ("Algernon") as the official Headline Sponsor for Wonderland, the world-leading event in the psychedelic medicine industry. The highly anticipated gathering is coming back to Miami from November 3-5th, 2022, at the Mana Wynwood Convention Centre in Miami's... Read More

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce that it will be the Headline Sponsor for Wonderland, the world-leading academic and business gathering in the psychedelic medicine industry, which will be held in Miami from November 3-5th, 2022 at the Mana Wynwood Convention Centre.... Read More

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to report positive results from the full data set of its Phase 2a Study evaluating NP-120 (“Ifenprodil”) for the potential treatment of idiopathic pulmonary fibrosis (“IPF”) and chronic cough. The full data set includes additional secondary measures... Read More

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to announce that its largest shareholder, AlphaNorth Asset Management (“AlphaNorth”), has increased its ownership position in the Company by acquiring 150,000 shares in the recent private placement financing. As a result, AlphaNorth now beneficially owns or has control or direction over, directly, or indirectly,... Read More

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce it has closed its previously announced non-brokered private placement in the amount of 373,900 units of the Company (the “Units”) at a price of $3.75 per Unit for gross proceeds of $1,402,125 (the “Offering”). Each Unit consists of one Class A... Read More

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce a non-brokered private placement for gross proceeds of $1,402,125 (the “Offering”) of units (the “Units”) at an issue price of $3.75 per Unit. Each Unit will consist of one Class A common share in the capital of the Company (a “Common Share”) and... Read More

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce it has been invited to present the results from its Phase 2a Study of NP-120 (“Ifenprodil”) for idiopathic pulmonary fibrosis (“IPF”) and Chronic Cough, at the 9 th American Cough Conference in June, 2023. The American Cough Conference is... Read More

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce additional results from its Phase 2a Study of NP-120 (“Ifenprodil”) for idiopathic pulmonary fibrosis (“IPF”) and chronic cough. After further review of the topline data, Ifenprodil was shown to be much more effective at reducing cough in... Read More

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce positive topline data showing that it has met the co-primary endpoint in its Phase 2 proof of concept study evaluating NP-120 (“Ifenprodil”) for the potential treatment of idiopathic pulmonary fibrosis (“IPF”) and chronic cough. In the... Read More

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage Canadian pharmaceutical development company, is pleased to provide an update on its chronic kidney disease (“CKD”) research program with NP-251 (“Repirinast”). In Q1 2022, the Company announced that it had initiated a new CKD research program to investigate Repirinast as part of its drug repurposing... Read More

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage Canadian pharmaceutical development company, is pleased to provide an update on its planned Phase 1 clinical human study of AP-188 (“N,N-dimethyltryptamine” or “DMT”). DMT is a known psychedelic compound that is part of the tryptamine family. The Company is currently working to complete the intravenous... Read More

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to disclose that as part of its intellectual property patent applications filed in early 2021 for AP-188 (“N,N-dimethyltryptamine” or “DMT”), the Company included nicotinate and pamoate as novel salt forms of DMT. Nicotinate and pamoate are commonly used... Read More

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) is pleased to announce the closing of its previously announced marketed public offering of units of the Company (the “ Units ” or the “ Offered Securities ”) with Research Capital Corporation as the sole agent and sole bookrunner (the “ Agent ”). Pursuant to the offering, the Company issued 309,117 Units at a price of... Read More

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) is pleased to announce the price of its previously announced marketed public offering of units of the Company (the “ Units ” or the “ Offered Securities ”) with Research Capital Corporation as the sole agent and sole bookrunner (the “ Agent ”), in each of the provinces of Canada (other than Quebec) (the “ Offering ”).... Read More

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has been issued a patent from the Canadian Intellectual Property Office (“CIPO”), No. 3101853, for the treatment of interstitial lung disease with NP-120 (“Ifenprodil”), entitled “Compositions and Methods for Treating Idiopathic... Read More

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, announces that patients from multiple sites participating in its Phase 2 proof of concept study of NP-120 (“Ifenprodil”) for idiopathic pulmonary fibrosis (“IPF”) and chronic cough, being conducted in Australia and New Zealand, have requested ongoing supply of... Read More

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) is pleased to announce that it is undertaking a marketed public offering of units of the Company (the “ Units ” or the “ Offered Securities ”) with Research Capital Corporation as the sole agent and sole bookrunner (the “ Agent ”), in each of the provinces of Canada (other than Quebec) (the “ Offering ”). The size of the... Read More

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that its Phase 2 proof-of-concept study of NP-120 (“Ifenprodil”) for idiopathic pulmonary fibrosis (“IPF”) and chronic cough has reached database lock. This means that all data from the trial is now finally reported, cleaned and "locked" in the... Read More

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that the last patient has completed the treatment period in its Phase 2 proof of concept study of NP-120 (“Ifenprodil”) for idiopathic pulmonary fibrosis (“IPF”) and chronic cough. The Company is projecting that topline data will be available in... Read More

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that its lead chronic kidney disease (“CKD”) drug NP-251 (“Repirinast”), reduced fibrosis by 56% with statistical significance, in a preclinical study investigating non-alcoholic steatohepatitis (“NASH”) in the STAM™ mouse model from SMC... Read More